Condition
CRS - Cytokine Release Syndrome
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06377059Not ApplicableRecruiting
Early Detection of Complications During Immunotherapy for Haematological Malignancy
NCT05306080Early Phase 1RecruitingPrimary
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
NCT07106671Phase 2RecruitingPrimary
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Showing all 3 trials